MedPath

Evaluation of Acute Lower Limb Ischemia

Completed
Conditions
Acute Limb Ischemia
Interventions
Procedure: Revascularization
Procedure: Primary major amputation
Other: Best medical treatment
Registration Number
NCT05138679
Lead Sponsor
Medical University Innsbruck
Brief Summary

The primary objective of this study is to evaluate the effect of different treatment modalities on clinical outcome of patients suffering from acute lower limb ischemia (ALI). Depending on clinical presentation, anatomical as well as technical considerations, different treatment options are available for revascularisation of affected limbs. Using an observational, international, multicentric study design (min. patient number of 500), the defined primary endpoint of the study, amputation-free survival 90 days after the diagnosis of ALI, will be evaluated.

Detailed Description

Recently published clinical guidelines highlighted that the available evidence on the management of acute lower limb ischemia (ALI) is mostly outdated and includes only small patient cohorts. Depending on the patient's characteristics, the duration of ischemic symptoms as well as the cause of ALI and the anatomical lesion, different treatment options are available and need to be compared regarding clinical outcome.

With the knowledge about the heterogeneity of patients suffering from ALI, a multicentre observational study design has the potential to give results on influence of several factors (patient related factors, treatment related factors) on clinical outcome of patients with lower extremity ALI. In contrast, a randomized controlled trial would not be feasible as heterogeneity of patients would lead to limitations in the recruitment of patients.

The primary objective of this study is to evaluate the effect of different treatment modalities on clinical outcome of patients suffering from acutle lower limb ischemia. Depending on clinical presentation, anatomical as well as technical considerations, different treatment options are available for revascularisation of affected limbs. Using an observational, international, multicentric study design (min. patient number of 500), the defined primary endpoint of the study, amputation-free survival 90 days after the diagnosis of ALI, will be evaluated.

The secondary objectives of this study are the identification of factors having an effect on the primary endpoint . These factors are:

* Demographic data (age, gender, Body Mass Index,

* Cardiovascular risk factors (diabetes, arterial hypertension, dyslipidemia, smoking history)

* COVID-19 anamnesis (infectious status; vaccination status)

* Pre-existing diseases (Arterial fibrillation, chronic kidney disease, hemodialysis, coronary artery disease, COVID infection in medical history, pulmonary disease)

* Risk factors for ALI (peripheral arterial disease, aortic aneurysm or dissection, arterial embolization in medical history, malignant disease, peripheral arterial aneurysm, previous stroke, thrombophilia, revascularization procedure on ipsilateral limb)

* Pre-existing medication (antiplatelet, oral anticoagulation, statins)

* Clinical presentation (Rutherford ischemia classification, Cause of ALI, anatomical level of arterial occlusion, diagnostic imaging modality)

* Details on performed intervention (time of ischemia, periprocedural heparin administration, type of procedure, technical details on performed procedure, compartment syndrome with need for fasciotomy)

* Outcome parameters (Survival, Rutherford ischemia classification, residual sensory or motor deficit, impaired walking distance, need for reintervention, major bleeding periprocedural, access site complications, organ failure) 30 and 90 days after diagnosis of ALI.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
700
Inclusion Criteria
  • Acute lower limb ischemia (Rutherford Categories I-III)
Exclusion Criteria
  • No informed consent

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Acute lower limb ischemiaPrimary major amputationPatients with acute lower limb ischemia (older than 18 years)
Acute lower limb ischemiaRevascularizationPatients with acute lower limb ischemia (older than 18 years)
Acute lower limb ischemiaBest medical treatmentPatients with acute lower limb ischemia (older than 18 years)
Primary Outcome Measures
NameTimeMethod
Amputation free survival - rate90 days

Rate of amputation free survival after diagnosis of acute lower limb ischemia

Secondary Outcome Measures
NameTimeMethod
Limb salvage rate90 days

Rate of patients not requiring major amputation.

Survival rate90 days

Rate of patients surviving the diagnosis of acute limb ischemia until the end of follow-up

Re-intervention rate of the index leg90 days

Rate of re-intervention for revascularization or complications of the index-leg

Clinical outcome of the index leg (Rutherford category)90 days

Clinical symptoms at the end of follow up (Rutherford category)

Complication rate90 days

Rate of complications after the diagnosis of acute limb ischemia (access site infection, acute kidney injury, periprocedural major bleeding, compartment syndrome, multi organ failure)

Trial Locations

Locations (37)

Amsterdam University Medical Center, Department of Surgery

🇳🇱

Amsterdam, Netherlands

Medical University of Innsbruck, Department of Vascular Surgery

🇦🇹

Innsbruck, Austria

Department of General Surgery, Division of Vascular Surgery, Medical University of Vienna

🇦🇹

Vienna, Austria

Department of Vascular Surgery, Hospital of Antibes Juan-les-Pins

🇫🇷

Antibes, France

Department of Vascular and Endovascular Surgery, Hospital Ottakring

🇦🇹

Vienna, Austria

Department of Cardio-Vascular Surgery, Clinic Floridsdorf and Karl Landsteiner Institute for Cardio-Vascular Research

🇦🇹

Vienna, Austria

University Hospital Merkur

🇭🇷

Zagreb, Croatia

Department of Vascular Surgery, Bordeaux University Hospital

🇫🇷

Bordeaux, France

Department of Vascular and Endovascular Surgery, Brest University Hospital

🇫🇷

Brest, France

Department of Vascular Surgery, Henri Mondor University Hospital

🇫🇷

Créteil, France

Department of Vascular Surgery, Ambroise Paré University Hospital, Assistance Publique-Hôpitaux de Paris

🇫🇷

Boulogne-Billancourt, France

Department of Vascular Surgery, University Hospital of Dijon

🇫🇷

Dijon, France

Vascular Surgery Department, Hospices Civils de Lyon

🇫🇷

Lyon, France

Department of Vascular Surgery, University Hospital of Nancy

🇫🇷

Nancy, France

Department of Vascular Surgery, Ambroise Paré University Hospital, Boulogne-Billancourt and Simone Veil Health Sciences Medical School, Versailles-Saint-Quentin-en-Yvelines University and Paris-Saclay University

🇫🇷

Paris, France

Vascular Surgery Department, Georges Pompidou European Hospital, APHP, Paris University

🇫🇷

Paris, France

Department of Vascular and Thoracic Surgery, Bichat Hospital, Paris, Université de Paris

🇫🇷

Paris, France

University Hospital of Nice, Université Côte d'Azur

🇫🇷

Nice, France

CHU Nantes, l'institut du thorax, service de chirurgie cardio-vasculaire

🇫🇷

Nantes, France

Department of Vascular Surgery, CHU de Reims

🇫🇷

Reims, France

European Vascular Center Aachen-Maastricht, University Hospital Aachen, RWTH Aachen University

🇩🇪

Aachen, Germany

Department of Vascular Surgery and Kidney Transplantation, University Hospitals of Strasbourg

🇫🇷

Strasbourg, France

University Hospital Cologne

🇩🇪

Cologne, Germany

Division of Vascular and Endovascular Surgery Department for Visceral-, Thoracic and Vascular Surgery Medical Faculty Carl Gustav Carus and University Hospital Carl Gustav Carus Dresden Technische Universität Dresden

🇩🇪

Dresden, Germany

Department of Vascular and Endovascular Surgery, University Hospital Münster

🇩🇪

Münster, Germany

Department of Vascular- and Endovascular Surgery, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf

🇩🇪

Düsseldorf, Germany

University Hopspital Chișinău

🇲🇩

Chisinau, Moldova, Republic of

Department of Vascular and Endovascular Surgery, Heart and Vascular Center, Semmelweis University

🇭🇺

Budapest, Hungary

University Medical Center Utrecht, Department of Vascular Surgery

🇳🇱

Utrecht, Netherlands

Institute for Cardiovascular Disease, Belgrade

🇷🇸

Belgrade, Serbia

Clinic for Vascular and Endovascular Surgery, Clinical Center of Serbia

🇷🇸

Belgrade, Serbia

Department of Cardiovascular Surgery, Inselspital, University of Bern

🇨🇭

Bern, Switzerland

Clinic for Vascular Surgery, Clinical Center Niš

🇷🇸

Niš, Serbia

Department of Vascular Surgery, Kantonsspital Winterthur

🇨🇭

Winterthur, Switzerland

Bristol Centre for Surgical Research, Bristol NIHR Biomedical Research Centre, University of Bristol

🇬🇧

Bristol, United Kingdom

Department of Vascular Surgery, University Hospital Wales

🇬🇧

Cardiff, United Kingdom

NHS Lothian

🇬🇧

Edinburgh, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath